Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is...

Full description

Saved in:
Bibliographic Details
Published inClinical and molecular hepatology Vol. 28; no. 3; pp. 380 - 395
Main Authors Myung Ji Goh, Dong Hyun Sinn
Format Journal Article
LanguageKorean
Published 대한간학회 01.07.2022
Subjects
Aspirin
Chemoprevention
Hepatocellular carcinoma
Statins
Online AccessGet full text

Cover

More Information
Summary:Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention of hepatocellular carcinoma (HCC). However, observational data is prone to bias, and no prospective randomized trials are currently available to assess the risks and benefits of statin or aspirin therapy for chemoprevention of HCC. It is therefore important for clinicians and researchers to be aware of the quality of current evidence regarding this issue. In this review, we summarize currently available evidence to assist clinicians with their decision to use statin or aspirin and provide information for further clinical investigations. (Clin Mol Hepatol 2022;28:380-395)
Bibliography:The Korean Association for the Study of the Liver
ISSN:2287-2728
2287-285X